In the year when GLP-1 drugs have become the centerpiece of American diabetes and obesity treatment, when Medicare is preparing to launch a $50/month Wegovy copay program on July 1, when the oral Wegovy pill has generated 1.3 million prescriptions in its first quarter, and when a Penn Medicine study just confirmed a 30% breast cancer risk reduction for women on these drugs, a Stanford Medicine study published Genome Medicine in April 2026 and surfacing widely in medical news this week reveals a finding that every patient, every prescribing physician, and every insurer building GLP-1 formulary strategies needs to understand.
The study finds that approximately 10% of the general population carries genetic variants that make them significantly less responsive to GLP-1 receptor agonists. For these individuals, estimated at roughly 33 million Americans, drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may not work as expected for blood sugar control, regardless of dose or adherence. Researchers also note that regions with high diabetes burden may have large numbers of these non-responders who have not yet been identified.
